Table 1.
Clinical characteristics of patients with BLMM and systemic treatments administrated after diagnosis of BLMM (n = 4727)
| Total |
HER2− |
HER2-low |
HER2+ |
|
|---|---|---|---|---|
| (N = 4727) | (n = 2247) | (n = 1222) | (n = 1258) | |
| Age at dBLMM | ||||
| Median (range) | 58 (20-95) | 58 (25-95) | 60 (27-88) | 55 (20-91) |
| Histological grade of initial diagnosis, n (%) | ||||
| Grade I | 307 (6.9%) | 178 (8.4%) | 85 (7.3%) | 44 (3.7%) |
| Grade II | 2299 (51.4%) | 1058 (49.6%) | 668 (57.6%) | 573 (48.4%) |
| Grade III | 1869 (41.7%) | 896 (42.0%) | 406 (35.0%) | 567 (47.9%) |
| Missing | 252 | 115 | 63 | 74 |
| Number of metastatic sites at metastatic diagnosis | ||||
| Median (range) | 2 (1.0-11.0) | 2 (1.0-10.0) | 2 (1.0-11.0) | 2 (1.0-9.0) |
| Metastasis-free interval (MFI) | ||||
| Median (range) | 24.7 (−2.8 to 591.7) | 27.2 (−2.8 to 591.7) | 30.3 (−1.9 to 482.0) | 14.7 (−2.7 to 400.5) |
| Hormone receptor status at dBLMM, n (%) | ||||
| Negative | 1746 (36.9%) | 868 (38.6%) | 297 (24.3%) | 581 (46.2%) |
| Positive | 2981 (63.1%) | 1379 (61.4%) | 925 (75.7%) | 677 (53.8%) |
| Timing of BLMM, n (%) | ||||
| At mBC diagnosis | 1192 (25.2%) | 540 (24.0%) | 278 (22.7%) | 374 (29.7%) |
| After mBC diagnosis | 3535 (74.8%) | 1707 (76.0%) | 944 (77.3%) | 884 (70.3%) |
| Interval from mBC to BLMM in months for patients with BLMM after mBC diagnosis (n = 3535) | ||||
| Median (range) | 18.0 (1.0-105.2) | 16.8 (1.0-104.0) | 20.9 (1.0-105.2) | 18.0 (1.0-93.5) |
| Number of line before dBLMM | ||||
| Median (range) | 1.0 (0.0-16.0) | 1.0 (0.0-11.0) | 2.0 (0.0-16.0) | 1.0 (0.0-12.0) |
| At least one treatment line administrated following dBLMM, n (%) | 3577 (75.7%) | 1723 (76.7%) | 908 (74.3%) | 946 (75.2%) |
| Number of lines for patients treated after dBLMM (n = 3577), n (%) | ||||
| Median (range) | 2 (1-12) | 2 (1-11) | 2 (1-12) | 2 (1-11) |
| 1rst line | 1329 (37.1%) | 615 (35.6%) | 309 (34.0%) | 405 (42.8%) |
| 2nd line | 926 (25.9%) | 399 (23.2%) | 202 (22.2%) | 325 (34.3%) |
| 3rd line | 508 (14.2%) | 265 (15.4%) | 124 (13.7%) | 119 (12.6%) |
| 4th line or more | 814 (22.8%) | 444 (25.8%) | 273 (30.1%) | 97 (10.3%) |
| Type of treatment administrated for patients treated after dBLMM (n = 3577), n (%) | ||||
| Endocrine therapy | 1026 (28.7%) | 492 (28.6%) | 307 (33.8%) | 227 (24.0%) |
| Chemotherapy | 2747 (76.8%) | 1447 (84.0%) | 743 (81.8%) | 557 (58.9%) |
| Targeted therapy | 1064 (29.7%) | 269 (15.6%) | 148 (16.3%) | 647 (68.4%) |
| Antibody–drug conjugate | 234 (6.5%) | 7 (0.4%) | 6 (0.7%) | 221 (23.4%) |
| Immunotherapy | 32 (0.9%) | 22 (1.3%) | 9 (1.0%) | 1 (0.1%) |
BLMM, brain and leptomeningeal metastases; dBLMM, first BLMM diagnosis; HER2, human epidermal growth factor receptor 2; mBC, metastatic breast cancer.